Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

Aortic valve stenosis' is an often-overlooked condition and a growing health concern in ageing societies such as Thailand. With an increasing elderly population and a rise in age-related valve ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

BACKGROUND: Despite reported racial disparities between Black and White adults in short-term outcomes after abdominal aortic ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

Cardiothoracic Surgeon Geoffrey R. Cousins, MD, FACS, left, and Interventional Cardiologist Jason Schott, DO, mark the 100th transcatheter aortic valve replacement procedure performed at Memorial ...